Do not administer IV. Transferring to another type or brand, changes in strength, species &/or method of manufacture of insulin. Less pronounced or different early warning symptoms of hypoglycemia in conditions including long duration of diabetes, intensified insulin therapy, diabetic nerve disease or medications (eg, β-blockers). Uncorrected hypoglycemic & hyperglycemic reactions. Inadequate use of dosages or discontinuation of treatment may lead to hyperglycemia & diabetic ketoacidosis especially in insulin-dependent diabetics. Insulin requirements may be increased during illness or emotional disturbances. Patients who undertake increased physical activity or change in the usual diet. Observe for signs & symptoms of heart failure, wt gain & edema if used in combination w/ pioglitazone; discontinue pioglitazone if any deterioration in cardiac symptoms occurs. Instruct patients to perform continuous rotation of the inj site to reduce the risk of developing lipodystrophy & cutaneous amyloidosis. Monitor blood glucose after the change in inj site & adjust dose of antidiabetics. May impair ability to drive or operate machinery. Renal & hepatic impairment. Pregnancy & lactation. Childn <12 yr.
A10AD04 - insulin lispro ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Sign Out
